These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 19355843)

  • 1. Cholinesterase inhibitors and beyond.
    Pepeu G; Giovannini MG
    Curr Alzheimer Res; 2009 Apr; 6(2):86-96. PubMed ID: 19355843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
    Kabir MT; Uddin MS; Begum MM; Thangapandiyan S; Rahman MS; Aleya L; Mathew B; Ahmed M; Barreto GE; Ashraf GM
    Curr Pharm Des; 2019; 25(33):3519-3535. PubMed ID: 31593530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.
    Haywood WM; Mukaetova-Ladinska EB
    Am J Geriatr Pharmacother; 2006 Sep; 4(3):273-86. PubMed ID: 17062329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
    Darreh-Shori T; Hosseini SM; Nordberg A
    J Alzheimers Dis; 2014; 39(2):423-40. PubMed ID: 24217282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
    Inglis F
    Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?
    Macdonald IR; Rockwood K; Martin E; Darvesh S
    J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinesterase inhibitors and memory.
    Pepeu G; Giovannini MG
    Chem Biol Interact; 2010 Sep; 187(1-3):403-8. PubMed ID: 19941841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could
    Jasiecki J; Wasąg B
    Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31601022
    [No Abstract]   [Full Text] [Related]  

  • 10. Cholinesterase inhibitors for Alzheimer's disease.
    Grutzendler J; Morris JC
    Drugs; 2001; 61(1):41-52. PubMed ID: 11217870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
    Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
    Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology and clinical efficacy of cholinesterase inhibitors.
    Jann MW
    Am J Health Syst Pharm; 1998 Nov; 55 Suppl 2():S22-5. PubMed ID: 9809108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
    Sharma P; Tripathi MK; Shrivastava SK
    Methods Mol Biol; 2020; 2089():257-286. PubMed ID: 31773661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholinesterases: new roles in brain function and in Alzheimer's disease.
    Giacobini E
    Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
    Standridge JB
    Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
    Greig NH; Lahiri DK; Sambamurti K
    Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
    Emre M
    Int J Clin Pract Suppl; 2002 Jun; (127):64-72. PubMed ID: 12139369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies.
    Darreh-Shori T; Soininen H
    Curr Alzheimer Res; 2010 Feb; 7(1):67-73. PubMed ID: 20205672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.